- Home
- LIPO vs PRFX Comparison
LIPO vs PRFX Comparison
Compare LIPO & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIPO
- PRFX
- Stock Information
- Founded
- LIPO 2005
- PRFX 2007
- Country
- LIPO United States
- PRFX Israel
- Employees
- LIPO N/A
- PRFX N/A
- Industry
- LIPO Biotechnology: Pharmaceutical Preparations
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- LIPO Health Care
- PRFX Health Care
- Exchange
- LIPO Nasdaq
- PRFX Nasdaq
- Market Cap
- LIPO 3.1M
- PRFX 3.6M
- IPO Year
- LIPO 2022
- PRFX 2020
- Fundamental
- Price
- LIPO $2.99
- PRFX $2.06
- Analyst Decision
- LIPO
- PRFX Hold
- Analyst Count
- LIPO 0
- PRFX 1
- Target Price
- LIPO N/A
- PRFX N/A
- AVG Volume (30 Days)
- LIPO 39.2K
- PRFX 55.9K
- Earning Date
- LIPO 05-14-2025
- PRFX 06-20-2025
- Dividend Yield
- LIPO N/A
- PRFX N/A
- EPS Growth
- LIPO N/A
- PRFX N/A
- EPS
- LIPO N/A
- PRFX N/A
- Revenue
- LIPO $519,866.00
- PRFX N/A
- Revenue This Year
- LIPO N/A
- PRFX N/A
- Revenue Next Year
- LIPO N/A
- PRFX N/A
- P/E Ratio
- LIPO N/A
- PRFX N/A
- Revenue Growth
- LIPO 8.88
- PRFX N/A
- 52 Week Low
- LIPO $1.97
- PRFX $1.68
- 52 Week High
- LIPO $12.00
- PRFX $18.17
- Technical
- Relative Strength Index (RSI)
- LIPO 58.50
- PRFX 51.59
- Support Level
- LIPO $2.75
- PRFX $1.93
- Resistance Level
- LIPO $3.17
- PRFX $2.11
- Average True Range (ATR)
- LIPO 0.29
- PRFX 0.10
- MACD
- LIPO 0.02
- PRFX 0.03
- Stochastic Oscillator
- LIPO 81.05
- PRFX 80.77
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.